The edge of what’s possible

Treeline has gathered capabilities that rarely live under the same roof: careful target selection, proven lab veterans working across disciplines, leading-edge technology, and investors who think big. We believe innovation cannot be outsourced. New and difficult targets require thoughtful assay development, innovative screening strategies and disciplined compound triage.

Our pipeline is target-centric, with programs spanning therapeutic areas and drug classes. We work on many programs in parallel. The scale of our pipeline should afford creative cost and risk sharing opportunities with pharma and financial partners in the future. We embrace the only definition of “platform” that matters to patients: repeatable success in the clinic.

Our clinical-stage programs are not proof of concept efforts or “shots on goal.” Each one is a serious effort to make a category-defining medicine, capable of changing the standard of care for a serious disease. For us, the medicines will be the measuring stick.

We were built to innovate a new biopharma R&D model, to prove it in the clinic, and to endure.